National Trends in the Outpatient Treatment of Children and Adolescents With Antipsychotic Drugs | Adolescent Medicine | JAMA Psychiatry | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.185.54. Please contact the publisher to request reinstatement.
1.
Martin  ALeslie  D Trends in psychotropic medication costs for children and adolescents, 1997-2000.  Arch Pediatr Adolesc Med 2003;157997- 1004PubMedGoogle ScholarCrossref
2.
Patel  NCSanchez  RJJohnsrud  MTCrismon  ML Trends in antipsychotic use in a Texas Medicaid population of children and adolescents: 1996 to 2000.  J Child Adolesc Psychopharmacol 2002;12221- 229PubMedGoogle ScholarCrossref
3.
Cooper  WOHickson  GBFuchs  CArbogast  PGRay  WA New users of antipsychotic medications among children enrolled in TennCare.  Arch Pediatr Adolesc Med 2004;158753- 759PubMedGoogle ScholarCrossref
4.
Curtis  LHMasselink  LEOstbye  THutchison  SDans  PEWright  AKrishnan  RRSchulman  KA Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States.  Arch Pediatr Adolesc Med 2005;159362- 366PubMedGoogle ScholarCrossref
5.
Rawal  PHLyons  JSMacIntyre  JCHunter  JC Regional variation and clinical indicators of antipsychotic use in residential treatment: a four-state comparison.  J Behav Health Serv Res 2004;31178- 188PubMedGoogle Scholar
6.
Staller  JAWade  MJBaker  M Current prescribing patterns in outpatient child and adolescent psychiatric practice in central New York.  J Child Adolesc Psychopharmacol 2005;1557- 61PubMedGoogle ScholarCrossref
7.
National Center for Health Statistics, NAMCS description. http://www.cdc.gov/nchs/about/major/ahcd/namcsdes.htmAccessed July 7, 2005
8.
National Center for Health Statistics, 2002 NAMCS Micro-Data File Documentation.  Hyattsville, Md Data File Coordinator, National Center for Health Statistics2003;
9.
National Center for Health Statistics, Using ultimate cluster methods with NAMCS and NHAMCS public use files. http:/www.cdc.gov/nachs/data/ahcd/ultimatecluster.pdfAccessed June 3, 2005
10.
Pottick  KJMcAlpine  DDAndelman  RB Changing patterns of psychiatric inpatient care for children and adolescents in general hospitals, 1988-1995.  Am J Psychiatry 2000;1571267- 1273PubMedGoogle ScholarCrossref
11.
US Census Bureau, Census 2000 summary file 1 (SF 1) 100-percent data: tables PCT12, PCT12A, and PCT12H. http://factfinder.census.govAccessed April 17, 2005
12.
Shah  BVBarnwell  BGDieler  GS SUDAAN User's Manual, Release 7.5.  Research Triangle Park, NC Research Triangle Institute1997;
13.
Olfson  MMarcus  SCWeissman  MMJensen  PS National trends in the use of psychotropic medications by children.  J Am Acad Child Adolesc Psychiatry 2002;41514- 521PubMedGoogle ScholarCrossref
14.
Zito  JMSafer  DJDosReis  SGardner  JFMagder  LSoeken  KBoles  MLynch  FRiddle  MA Psychotropic practice patterns for youth: a 10-year perspective.  Arch Pediatr Adolesc Med 2003;15717- 25PubMedGoogle ScholarCrossref
15.
Correll  CULeucht  SKane  JM Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.  Am J Psychiatry 2004;161414- 425PubMedGoogle ScholarCrossref
16.
Leslie  DLRosenheck  RAHorwitz  SM Patterns of mental health utilization and costs among children in a privately insured population.  Health Serv Res 2001;36113- 127PubMedGoogle Scholar
17.
Leslie  DLRosenheck  R Changes in inpatient mental health utilization and costs in a privately insured population, 1993 to 1995.  Med Care 1999;37457- 468PubMedGoogle ScholarCrossref
18.
Stigler  KAPotenza  MNPosey  DJMcDougle  CJ Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management.  Paediatr Drugs 2004;633- 44PubMedGoogle ScholarCrossref
19.
Toren  PRatner  SLaor  NWeeizman  A Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.  Drug Saf 2004;271135- 1156PubMedGoogle ScholarCrossref
20.
Pappagallo  MSilva  R The effect of atypical antipsychotic agents on prolactin levels in children and adolescents.  J Child Adolesc Psychopharmacol 2004;14359- 371PubMedGoogle ScholarCrossref
21.
Findling  RLMcNamara  NK Atypical antipsychotics in the treatment of children and adolescents: clinical applications.  J Clin Psychiatry 2004;65 ((suppl 6)) 30- 44PubMedGoogle Scholar
22.
Sikich  LHamer  RMBashford  RASheitman  BBLieberman  JA A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.  Neuropsychopharmacology 2004;29133- 145PubMedGoogle ScholarCrossref
23.
King  BZwi  KNonn  KLongworth  JDossetor  D Use of risperidone in a paediatric population: an observational study.  J Paediatr Child Health 2003;39523- 527PubMedGoogle ScholarCrossref
24.
Wolraich  MLHannah  JNPinnock  TYBaumgaertel  ABrown  J Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample.  J Am Acad Child Adolesc Psychiatry 1996;35319- 324PubMedGoogle ScholarCrossref
25.
Lanzi  GZambrino  CATermine  CPalestra  MFerrari-Ginevra  OOrcesi  SManfredi  PBeghi  E Prevalence of tic disorders among primary school students in the city of Pavia, Italy.  Arch Dis Child 2004;8945- 47PubMedGoogle Scholar
26.
Khalifa  Nvon Knorring  AL Prevalence of tic disorders and Tourette syndrome in a Swedish school population.  Dev Med Child Neurol 2003;45315- 319PubMedGoogle ScholarCrossref
27.
Constantino  JNTodd  RD Autistic traits in the general population: a twin population.  Arch Gen Psychiatry 2003;60524- 530PubMedGoogle ScholarCrossref
28.
Steffenburg  SGollberg  C Autism and autistic-like conditions in Swedish rural and urban areas: a population study.  Br J Psychiatry 1986;14981- 87PubMedGoogle ScholarCrossref
29.
Zito  JMSafer  DJZuckerman  IHGardner  JFSoeken  K Effect of Medicaid eligibility category on racial disparities in the use of psychotropic medications among youths.  Psychiatr Serv 2005;56157- 163PubMedGoogle ScholarCrossref
30.
Delbello  MPSchwiers  MLRosenberg  HLStrakowski  SM A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania.  J Am Acad Child Adolesc Psychiatry 2002;411216- 1223PubMedGoogle ScholarCrossref
31.
Frazier  JABiederman  JTohen  MFeldman  PDJacobs  TGToma  VRater  MATarazi  RAKim  GSGarfield  SBSohma  MGonzalez-Heydrich  JRisser  RCNowlin  ZM A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder.  J Child Adolesc Psychopharmacol 2001;11239- 250PubMedGoogle ScholarCrossref
32.
Frazier  JAMyer  MCBiederman  JWozniak  JWilens  TESpencer  TJKim  GSShapiro  S Risperidone treatment for juvenile bipolar disorder: a retrospective chart review.  J Am Acad Child Adolesc Psychiatry 1999;38960- 965PubMedGoogle ScholarCrossref
33.
Calabrese  JRKeck  PEMacFadden  WMinkwitz  MKetter  TAWeisler  THCutler  AJMcCoy  RWilson  EMullen  JBOLDER Study Group, A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.  Am J Psychiatry 2005;1621351- 1360PubMedGoogle ScholarCrossref
34.
Tohen  MVieta  ECalabrese  JKetter  TASachs  GBowden  CMitchell  PBCentorrino  FRisser  RBaker  RWEvans  ARBeymer  KDube  STollefson  GDBrier  A Efficacy of olanzapine and olanzapine-combination in the treatment of bipolar I depression.  Arch Gen Psychiatry 2003;601079- 1088PubMedGoogle ScholarCrossref
35.
Kaye  JABradbury  BDJick  H Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study.  Br J Clin Pharmacol 2003;56569- 575PubMedGoogle ScholarCrossref
36.
Blanco  CGoodwin  RDLiebowitz  MRSchmidt  ABLewis-Fernandez  ROlfson  M Use of psychotropic medications for patients with office visits who receive a diagnosis of panic disorder.  Med Care 2004;421242- 1245PubMedGoogle ScholarCrossref
37.
McCracken  JTMcGough  JShah  BCronin  PHong  DAman  MG Risperidone in children with autism and serious behavioral problems.  N Engl J Med 2002;347314- 321PubMedGoogle ScholarCrossref
38.
McDougle  CJScahill  LAman  MGMcCracken  JTTierney  EDavies  MArnold  LEPosey  DJMartin  AGhuman  JKShah  BChuang  SZSwiezy  NBGonzalez  NMHollway  JKoenig  KMcGough  JJRitz  LVitiello  B Risperidone for the core symptom domains of autism: results from the study by autism network of the Research Units on Pediatric Psychopharmacology.  Am J Psychiatry 2005;1621142- 1148PubMedGoogle ScholarCrossref
39.
Shea  STurgay  ACarroll  ASchulz  MOrlik  HSmith  IDunbar  F Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.  Pediatrics 2004;114e634http://www.pediatrics.orgAccessed March 17, 2006Google ScholarCrossref
40.
Aman  MGDeSmedt  GDerivan  ALyons  BFindling  RLRisperidone Disruptive Behavior Study Group, Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.  Am J Psychiatry 2002;1591337- 1346PubMedGoogle ScholarCrossref
41.
Snyder  RTurgay  AAman  MBinder  CFisman  SCarroll  ARisperidone Conduct Study Group, Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.  J Am Acad Child Adolesc Psychiatry 2002;411026- 1036PubMedGoogle ScholarCrossref
42.
Dion  YAnnable  LSandor  PChouinard  G Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial.  J Clin Psychopharmacol 2002;2231- 39PubMedGoogle ScholarCrossref
43.
Scahill  LLeckman  JFSchultz  RTKatsovich  LPeterson  BS A placebo-controlled trial of risperidone in Tourette syndrome.  Neurology 2003;601130- 1135PubMedGoogle ScholarCrossref
44.
Kumra  SFrazier  JAJacobsen  LKMcKenna  KGordon  CTLenane  MCHamburger  SDSmith  AKAlbus  KEAlaghband-Rad  JRapoport  JL Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison.  Arch Gen Psychiatry 1996;531090- 1097PubMedGoogle ScholarCrossref
45.
Pappadopulos  EMacintyre  JC  IICrismon  MLFindling  RLMalone  RPDerivan  AFindling  RLMalone  RPDerivan  ASchooler  NSikich  LGreenhill  LSchur  SBFelton  CJKranzler  HRube  DMSverd  JFinnerty  MKetner  SSiennick  SEJensen  PS Treatment Recommendations for the Use of Atypical Antipsychotics for Aggressive Youth (TRAAY): part II.  J Am Acad Child Adolesc Psychiatry 2003;42145- 161PubMedGoogle ScholarCrossref
Original Article
June 2006

National Trends in the Outpatient Treatment of Children and Adolescents With Antipsychotic Drugs

Author Affiliations

Author Affiliations: New York State Psychiatric Institute and Department of Psychiatry, College of Physicians and Surgeons (Drs Olfson, Blanco, Liu, and Moreno), and Department of Biostatistics, Mailman School of Public Health (Dr Liu), Columbia University, New York; and Genetic Basis of Mood and Anxiety Disorders, Mood and Anxiety Program, National Institute of Mental Health, Bethesda, Md (Dr Laje).

Arch Gen Psychiatry. 2006;63(6):679-685. doi:10.1001/archpsyc.63.6.679
Abstract

Context  Although there are indications that antipsychotic drugs are increasingly used to treat children and adolescents, little is known about the characteristics of those who receive them.

Objective  To examine national trends and patterns in antipsychotic treatment of youth seen by physicians in office-based medical practice.

Design  Analysis of national trends of visits (1993-2002) that included prescription of antipsychotics, and comparison of the clinical and demographic characteristics of visits (2000-2002) that included or did not include antipsychotic treatment.

Setting  Outpatient visits to physicians in office-based practice.

Participants  Patient visits by persons 20 years and younger from the National Ambulatory Medical Care Surveys from 1993 to 2002.

Main Outcome Measures  Visits that included prescription of antipsychotics.

Results  In the United States, the estimated number of office-based visits by youth that included antipsychotic treatment increased from approximately 201 000 in 1993 to 1 224 000 in 2002. From 2000 to 2002, the number of visits that included antipsychotic treatment was significantly higher for male youth (1913 visits per 100 000 population) than for female youth (739 visits per 100 000 population), and for white non-Hispanic youth (1515 visits per 100 000 population) than for youth of other racial or ethnic groups (426 visits per 100 000 population). Overall, 9.2% of mental health visits and 18.3% of visits to psychiatrists included antipsychotic treatment. From 2000 to 2002, 92.3% of visits with prescription of an antipsychotic included a second-generation medication. Mental health visits with prescription of an antipsychotic included patients with diagnoses of disruptive behavior disorders (37.8%), mood disorders (31.8%), pervasive developmental disorders or mental retardation (17.3%), and psychotic disorders (14.2%).

Conclusions  There has been a sharp national increase in antipsychotic treatment among children and adolescents in office-based medical practice. Second-generation antipsychotics are being widely prescribed, and emerging empirical evidence provides a base of support that is limited to short-term safety and efficacy.

×